Vincenzo Trapanese

Dr. Vincenzo Trapanese

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Life
Verified
Journal Article
Open access
PDF file
VTVincenzo Trapanese
Vincenzo Trapanese
ADAnnamaria Dagostino
Annamaria Dagostino
MNMaria Resilde Natale
Maria Resilde Natale
FGFederica Giofrè
Federica Giofrè
CVClara Vatalaro
Clara Vatalaro
FAFranco Arturi
Franco Arturi
Obesity, insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic syndrome have been largely correlated to a reduction in bacterial load and diversity, resulting in a condition known as intestinal dysbiosis. The recent emergence of novel antidiabetic medications has been demonstrated to exert a favourable influence on the composition of the intestinal microbiota. Incretin-based therapy exerts a multifaceted influence on the composition of the gut microbiota, leading to alterations in bacterial flora. Of particular significance is the capacity of numerous metabolites produced by the gut microbiota to modulate the activity and hormonal secretion of enteroendocrine cells. This review examines the effects of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/gastric inhibitory polypeptide (GIP) receptor dual agonists on the composition of the gut microbiota in both mice and human subjects. The nature of this interaction is complex and bidirectional. The present study demonstrates the involvement of the incretinic axis in modulating the microbial composition, with the objective of providing novel preventative strategies and potential personalised therapeutic targets for obesity and T2DM.

4 April 2024 in Italian Journal of Medicine
Verified
Journal Article
Open access
PDF file
VTVincenzo Trapanese
Vincenzo Trapanese
FMFrancesco Maruca
Francesco Maruca
MNMaria Resilde Natale
Maria Resilde Natale
FGFederica Giofrè
Federica Giofrè
FCFrancesca Cosentino
Francesca Cosentino
FAFranco Arturi
Franco Arturi
Ketoacidosis is considered an emergency metabolic disorder that can be triggered by starvation and alcohol consumption in addition to diabetes. We described an unusual case of ketoacidosis in a non-diabetic young man who presented to our hospital with a complaint of rapid and shallow breathing, weakness and nausea. Fourteen days back, due to heart failure, he started sodiumglucose co-transporter 2 inhibitors (SGLT2-i) in addition to fumarate bisoprolol, sacubitril/valsartan and eplerenone. Based on clinical examination, ketoacidosis was suspected, although his glucose and glycosylated hemoglobin levels were in range. Overall, based on the clinical and laboratory findings, the diagnosis of euglycemic non-diabetic ketoacidosis due to the use of the SGLT2- i was made and SGLT2-i has been discontinued. Although SGLT2-i are effective and safe drugs, it is advisable to carefully evaluate their use also in non-diabetic patients especially when hepatic fibrosis or incorrect eating habits are present.

9 January 2024 in Italian Journal of Medicine
Verified
Journal Article
Open access
PDF file
FGFederica Giofrè
Federica Giofrè
VTVincenzo Trapanese
Vincenzo Trapanese
MNMaria Resilde Natale
Maria Resilde Natale
CVClara Vatalaro
Clara Vatalaro
FCFrancesca Cosentino
Francesca Cosentino
FAFranco Arturi
Franco Arturi
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RAs) approved for the treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity. GLP-1RAs are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease. These agents prevent renal complications and have proven beneficial effects on cardiac outcomes. We describe a rare case of semaglutide-induced acute kidney injury (AKI) in a young woman with obesity, T2DM, hypertensive cardiomyopathy, and no pre-existing chronic kidney disease (CKD). This case is relevant as GLP1-RAs is used frequently in patients with and without kidney disease. Currently, only 3 cases of AKI ascribed to semaglutide of which only 1 without CKD have been described. Only in this case, kidney function improves after semaglutide discontinuation. However, because GLP1-RAs will be prescribed more and more frequently, we sought to highlight this possible, serious adverse effect of semaglutide.

3 July 2024 in Italian Journal of Medicine
Verified
Journal Article
Open access
PDF file
VTVincenzo Trapanese
Vincenzo Trapanese
MPMaria Chiara Pelle
Maria Chiara Pelle
MCMaria Capria
Maria Capria
NCNazareno Carullo
Nazareno Carullo
CVClara Vatalaro
Clara Vatalaro
FAFranco Arturi
Franco Arturi
The very low-calorie ketogenic diet (VLCKD), characterized by a marked energy restriction that induces rapid weight loss, has recently been proposed as a valid nutritional strategy for managing obesity. VLCKD is commonly considered dangerous for the kidneys due to the misconception that it is high in protein, beyond the risk of electrolyte imbalances and an increase in diuresis. We report a case of safe and effective weight loss induced by VLCKD in a 43-year-old Caucasian woman with a recent episode of acute kidney injury on advanced chronic kidney disease. Surprisingly, we observed that after the diet-induced weight loss, not only did renal function not worsen, but proteinuria also improved. The principal value of this case report is its singular demonstration of impressive weight loss induced by VLCKD in a complex obese patient that was apparently not accompanied by the development of serious adverse sequelae.